IRCT20240804062647N81 IRCT 2026-11-07 Abidi Pharmaceutical Company Bioequivalence Study of Rimegepant 75 mg Orally Disintegrating Tablet (RIPEVA®) by Dr. Abidi Pharmaceutical Company In-vivo Bioequivalence Study of Rimegepant 75 mg Orally Disintegrating Tablet (RIPEVA®) of The Test Drug manufactured by Dr. Abidi Pharmaceutical Company in Compared with The Reference Drug NURTEC® 75 mg 2026-10-12 anticipated 24 Recruiting https://irct.ir/trial/93615 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Crossover, Purpose: Treatment, Randomization description: Initially, volunteers are screened according to the study inclusion and exclusion criteria, and 24 eligible volunteers are selected. Randomization is performed using Microsoft Excel and the RAND() function. For this purpose, random values are generated for numbers 1 to 24, and the order of these numbers is randomly determined based on the generated values. Each volunteer is then assigned a unique number according to the randomization list and receives an identification card containing the assigned number. During the first study period, volunteers assigned even numbers receive the reference drug (R), while those assigned odd numbers receive the test drug (T). In the second period, the treatments are switched in a crossover manner, so that volunteers who received the reference drug in the first period receive the test drug in the second period, and vice versa. The final randomization list is kept unchanged after preparation and used for study implementation, Blinding description: This study is a single-blind (participant) clinical trial Rimegepant 75 mg Orally Disintegrating Tablet (RIPEVA®) of The Test Drug manufactured by Dr. Abidi Pharmaceutical Company and the original brand are removed from their packaging by the operator and placed in identical, coded cans. Volunteers are unaware of the type of drug or test they are receiving. Bioequivalence This study is performed on healthy volunteers.. Intervention 1: Intervention group 1: Volunteers in this group will receive a single 75 mg dose of Rimegepant orally disintegrating tablet (RIPEVA), manufactured by Dr. Abidi Pharmaceutical Company (Test product), during the first study period. Following a one-week washout period, they will receive a single 75 mg dose of NURTEC ODT (Reference product) during the second study period. Intervention 2: Intervention group 2: Volunteers in this group will receive a single 75 mg dose of NURTEC ODT (Reference product) during the first study period. Following a one-week washout period, they will receive a single 75 mg dose of Rimegepant orally disintegrating tablet (RIPEVA), manufactured by Dr. Abidi Pharmaceutical Company (Test product), during the second study period. No - There is not a plan to make this available Justification or reason for not sharing IPD is These data are as secure between researchers and related industries.